内容来源：https://www.geekwire.com/2025/microsoft-co-founder-paul-allens-final-act-new-3-1b-foundation-bets-big-on-science-and-tech/

内容总结：

微软联合创始人保罗·艾伦虽已离世，但他对科技与未来的乐观信念正通过一个全新非营利基金会延续其影响力。由艾伦遗产中拨付31亿美元初始资金创立的"科学与技术基金"（FFST），将在未来四年投入至少5亿美元推动生物科学、环境及人工智能领域的突破性研究，首批1500万美元赠款已定向支持西雅图多家科研机构。

该基金会由免疫学专家琳达·斯图尔特博士领导，其使命完全遵循艾伦生前亲自制定的规划。艾伦的妹妹乔迪·艾伦担任基金会主席，董事会成员包括前微软CEO鲍尔默等长期合作伙伴。区别于主要支持社区文化项目的艾伦家族慈善体系，FFST专注于前沿科技的长期高风险投资。

基金会资金规模预计将继续扩大——艾伦遗产正在处置其NBA开拓者队等资产，所有出售所得将按遗嘱用于慈善事业。目前FFST已跻身美国顶级科技慈善机构行列，其独特定位在于聚焦原始创新，与盖茨基金会等侧重应用推广的机构形成互补。

首轮受助机构包括贝纳罗亚研究所、华盛顿大学环境学院等当地顶尖科研单位。这些赠款不仅助力关键研究，更在联邦科研经费紧缩的背景下为核心基础设施提供持续支持。正如斯图尔特博士所言，基金会旨在守护科研人员的梦想能力，以保罗·艾伦"预见未来"的视野继续推动人类进步。

中文翻译：

即便在生命最后岁月，微软联合创始人保罗·艾伦仍对科学、技术及世界的未来充满热忱——他在2017年接受GeekWire专访时坦言："我们正置身于一个充满无限可能的黄金时代。"这份乐观精神与他的财富影响力，将通过一个新成立的非营利基金会延续——该机构肩负着对未来进行大胆押注的使命。

依托这位已故微软联合创始人遗产中拨出的31亿美元初始捐赠资金，新成立的"科学与技术基金"将在未来四年内投入至少5亿美元，用于加速生物科学、环境保护及人工智能造福人类领域的突破性进展。首批1500万美元资助已定向投放至西雅图研究机构。

"我们的核心使命是提出宏大命题并创造深远影响，"总部位于西雅图的该基金会首席执行官琳达·斯图尔特博士表示。这位在免疫学与全球健康领域经验丰富的医学科学家接受GeekWire采访时强调：基金会的使命并非对艾伦意愿的解读，而是对其愿景的直接践行。早在2018年因非霍奇金淋巴瘤并发症去世前，艾伦已亲自指导基金会的创立方向与重点领域。

从早期与比尔·盖茨共同开发软件，到后期对科技领域的广泛投资，艾伦始终被誉为"思想者"。斯图尔特指出，数十年后的今天，生物科学、人工智能与环境领域不仅仍是前沿焦点，更成为最重要的研究方向，这印证了艾伦"预见未来的魔力"。

艾伦遗产代表确认，艾伦本人在规划中亲自任命了基金会董事会。其主席由艾伦胞姐乔迪·艾伦担任，成员包括多位与保罗·艾伦在不同领域密切合作的伙伴：

• 前微软CEO史蒂夫·鲍尔默（二人因参与NBA球队运营在微软后期结下深厚友谊）
• 艾伦研究所前CEO艾伦·琼斯（曾与艾伦共同建立具有全球影响力的生物科学研究机构）
• 托马斯·丹尼尔博士（艾伦研究所理事、华盛顿研究基金会即将离任的CEO）
• 南希·佩雷茨曼（长期投资顾问、艾伦公司董事总经理，曾为艾伦重大投资提供咨询）

"通过新基金会，我们将践行保罗的慈善愿景，"乔迪·艾伦在宣布这一里程碑的新闻稿中表示。这个非正式简称FFST的基金会成立，也标志着解答"艾伦自1986年微软上市所积累财富将何去何从"这一长期疑问取得重大进展。

虽然独立的艾伦家族慈善机构将继续支持各类社区与艺术项目（如近期向华盛顿州930个文化艺术组织捐赠1000万美元），但FFST的架构专为资助具有重大影响的科技项目而设计。

基金会是在长期处置艾伦众多资产（豪华地产、游艇、博物馆、艺术品、古董计算机等）过程中应运而生的，所得收益将集中用于其长期慈善优先事项。鉴于遗产规模与复杂性，遗产管理程序预计将持续数年。

随着NBA波特兰开拓者队及NFL西雅图海鹰队即将出售，FFST的捐赠基金未来可能大幅增长。艾伦遗产发言人杰森·汉克确认，球队出售收益将全部用于慈善事业，但未透露FFST是否获得主要份额，仅表示整体规划细节将在"适当时机公布"。

目前FFST已跻身美国顶级慈善机构行列，在科技领域可与西蒙基金会（35亿美元）、斯隆基金会（19亿美元）比肩。斯图尔特CEO曾担任华盛顿大学蛋白质设计研究所执行主任，更早前在盖茨基金会负责疫苗与生物制剂副主任工作。她阐释FFST与盖茨基金会（770亿美元规模）的差异：FFST更侧重于前沿科学探索，而盖茨基金会重在后期成果落地。

FFST初创团队仅六人，办公地点位于西雅图市中心以南的韦尔集团大厦（原艾伦旗下火神控股公司）。除持续资助华盛顿大学艾伦计算机科学与工程学院外，保罗·艾伦的遗产还包括创立艾伦研究所和独立的人工智能研究所AI2，两者目前仍由艾伦遗产资助。

尽管FFST最终将资助全球项目，但其首批资助策略性地聚焦艾伦故乡。首笔1500万美元投资西雅图"卓越中心"，旨在促进科学协作，强化该地区在FFST重点领域的领先地位。首批受助机构包括：

• 贝纳罗亚研究所：资助其35万份人类样本生物库及数据分析，加速解密人类免疫系统
• 华盛顿大学环境学院：通过实地观测与计算机模型预测环境变化，研发气候解决方案
• 弗雷德·哈钦森癌症中心：探索免疫系统对抗癌症及自身免疫性疾病机制，开发新型细胞疗法
• 西雅图儿童医院：推进儿童癌症与自身免疫疾病早期临床试验，开发安全、可即用的细胞治疗技术

新基金会成立之际，正值许多科研机构面临联邦资金紧缩的困境。首期受助方认为这一背景凸显了FFST的重要意义。贝纳罗亚研究所所长简·巴克纳博士指出，FFST资助核心基础设施的"独特视野"将惠及整个生物科学界；西雅图儿童医院治疗学首席医疗官科琳·德莱尼则表示，这笔资金在联邦科研支持受挫时期"为重塑科研效率提供独特机遇"。

斯图尔特强调，FFST并非填补联邦资金缺口，而是秉承更宏大的使命——延续艾伦在科技领域创造持久影响的愿景。"持续赋予人们梦想与重塑未来的能力至关重要，"她如是说。

英文来源：

Even in the final years of his life, Microsoft co-founder Paul Allen was as excited as ever about what the future would bring for science, technology, and the world — telling GeekWire in a 2017 interview, “It really is a golden age of what’s possible.”
Allen’s optimism — and the impact of his wealth — will live on in a new nonprofit foundation charged with making bold bets on the future.
With an initial $3.1 billion endowment from the late Microsoft co-founder’s estate, the new Fund for Science and Technology will deploy at least $500 million over the next four years to accelerate progress in bioscience, the environment, and AI for good — starting with $15 million in grants to Seattle research institutions.
“Our primary role is to ask big questions and have a big impact,” said Dr. Lynda Stuart, the CEO of the Seattle-based foundation, a physician-scientist with extensive experience in immunology and global health, in an interview with GeekWire.
The mission isn’t an interpretation of Allen’s wishes — it’s a direct implementation. Allen personally directed the foundation’s formation and focus areas before his 2018 death from complications of non-Hodgkin’s lymphoma.
From his early software work with Bill Gates to far-flung investments in tech and science, Allen was known as the “Idea Man.” Years later, the fact that bioscience, AI and the environment are not only still relevant but among the most important areas for research speaks to Allen’s “magical ability to see into the future,” Stuart said.
A representative of Allen’s estate confirmed that Allen himself also named the foundation’s board in his plans. It’s chaired by Allen’s sister, Jody Allen, and includes several others who knew and worked closely with Paul Allen in various capacities.

• Former Microsoft CEO Steve Ballmer, whose friendship with Allen was cemented in their post-Microsoft years over their involvement in the NBA.
• Allan Jones, former Allen Institute CEO, who worked directly with Allen to build the influential bioscience research organization.
• Dr. Thomas Daniel, Allen Institute board member and outgoing CEO of the Washington Research Foundation.
• Nancy Peretsman, a longtime investment advisor and managing director at investment bank Allen & Co. who counseled Allen on major investments.
  “With this new foundation, we’re bringing Paul’s philanthropic vision to bear,” said Jody Allen, in a news release announcing the milestone.
  The creation of the foundation, known informally FFST, is also a major step toward answering the longstanding question of what would happen to the wealth that Allen amassed starting with Microsoft’s 1986 stock market debut.
  While the separate Allen Family Philanthropies will continue to support a wide range of community and arts initiatives — such as its recent $10 million grant to 930 arts and culture organizations across Washington state — FFST is structured to handle large-scale funding for high-impact science and technology projects.
  The foundation is emerging from the extended process of selling many of Allen’s far-flung assets — luxury properties, yachts, museums, art, vintage computers, and more — and focusing the proceeds on his long-term philanthropic priorities. That process of estate administration is still under way, and it’s expected to continue for years given the size and complexity of what Allen left behind.
  FFST’s endowment could grow substantially in future years with the expected sale of the Portland Trail Blazers NBA franchise and eventually the Seahawks NFL team. The Allen estate recently reached a deal to sell the Blazers to the owner of the Carolina Hurricanes NHL team for a reported price of more than $4 billion.
  All proceeds from the sale of the teams will go to philanthropic causes, as Allen directed, confirmed Jason Hunke, a spokesperson for the Paul G. Allen Estate. Hunke declined to say whether FFST would get the bulk of the proceeds, explaining that details of the broader plan will be “revealed at the appropriate time” in the future.
  In the meantime, FFST already ranks among the top U.S. philanthropies, particularly in science and technology, in the realm of others such as the Simons Foundation ($3.5 billion), and the Alfred P. Sloan Foundation ($1.9 billion).
  Stuart, the FFST CEO, was previously executive director of the Institute for Protein Design at the University of Washington School of Medicine, and before that worked for the Gates Foundation, as deputy director for vaccines and biologics.
  She contrasted FFST’s approach with the Gates Foundation (the world’s largest philanthropy, with an endowment of $77 billion) by explaining that FFST is more of a “discovery organization” focused on frontier science, while the Gates Foundation does a significant amount of later-stage work focused on delivery into the field.
  FFST is starting with a team of six people, based in the building just south of downtown Seattle that houses Vale Group, the new name for what was previously known as Allen’s Vulcan holding company.
  In addition to providing major funding for the UW’s Allen School of Computer Science & Engineering, Paul Allen’s legacy includes starting the bioscience-focused Allen Institute and the separate Allen Institute for AI (Ai2), both of which the Allen estate funds.
  Allen estate spokesperson Hunke did not answer the question of whether FFST will eventually take over funding for the Allen Institute and AI2 as part of its bioscience and AI mandates, saying that the new foundation’s “funding priorities will be driven by its strategy, which will be revealed over time.”
  While FFST will eventually fund projects nationally and internationally, its inaugural grants are strategic investments in Allen’s hometown.
  Stuart explained that the initial $15 million investment in Seattle’s “centers of excellence” is designed in part to encourage more scientific collaboration, “to further strengthen the region as a powerhouse” in the areas where FFST is focusing.
  Initial grant recipients include:
• Benaroya Research Institute (BRI): Funding its massive biorepository of human samples and the data experts who study it, helping to figure out how the human immune system works, faster and more accurately.
• University of Washington, College of the Environment: To help tackle climate change by using real-world observations and computer models to predict future environmental shifts and find new solutions.
• Fred Hutchinson Cancer Center: To better understand how the immune system can fight cancer and autoimmune diseases, and to create new, safer treatments that use the body’s own cells.
• Seattle Children’s: To keep early-stage clinical trials going for kids with cancer and autoimmune diseases, and to develop new cell-based treatments that are safer, cheaper, and ready to go when a child needs them.
  The new foundation is launching at a time when many scientific organizations are feeling the strain of a challenging federal funding landscape, a backdrop that some of its inaugural grantees see as critical context for FFST’s arrival.
  The grant to the Benaroya Research Institute supports BRI’s biorepository, a library of over 350,000 biological samples collected from 15,000 people over two decades, which allows scientists to rapidly test new ideas about the immune system.
  Dr. Jane Buckner, BRI president, explained that this type of core infrastructure is vital for many projects but difficult to support through traditional, project-specific grants. In an unstable funding environment, long-term investments like the biorepository are often the first things to be cut, even though their value increases over time.
  It’s a “unique vision that they’ve brought to the table,” Buckner said of FFST’s efforts to fund resources that will help the broader bioscience community.
  The grant to Seattle Children’s will ensure continued funding for research and development of off-the-shelf cell therapies — treatments that can be made in advance and given to any patient without the need for custom, single-patient manufacturing.
  Dr. Colleen Delaney, VP and chief medical officer at Seattle Children’s Therapeutics, said the funding will help keep trials moving forward. She described it as critical at a time when federal support for scientific research has been under attack.
  For the broader community, Delaney said, FFST’s funding offers “a unique opportunity to bring us together and to reimagine how quickly we get things done.”
  Stuart said the new foundation doesn’t see its role as filling gaps left by federal funding cuts. Instead, she said, FFST will be guided by its larger mission, aligned with Allen’s vision of making a lasting impact in science and technology.
  “It’s really important for people to continue to be able to dream and to imagine a different future,” Stuart said.